» Articles » PMID: 27809936

Impact of Combined FDG-PET/CT and MRI on the Detection of Local Recurrence and Nodal Metastases in Thyroid Cancer

Abstract

Background: Suspected recurrence of thyroid carcinoma is a diagnostic challenge when findings of both a radio iodine whole body scan and ultrasound are negative. PET/CT and MRI have shown to be feasible for detection of recurrent disease. However, the added value of a consensus reading by the radiologist and the nuclear medicine physician, which has been deemed to be helpful in clinical routines, has not been investigated. This study aimed to investigate the impact of combined FDG-PET/ldCT and MRI on detection of locally recurrent TC and nodal metastases in high-risk patients with special focus on the value of the multidisciplinary consensus reading.

Materials And Methods: Forty-six patients with suspected locally recurrent thyroid cancer or nodal metastases after thyroidectomy and radio-iodine therapy were retrospectively selected for analysis. Inclusion criteria comprised elevated thyroglobulin blood levels, a negative ultrasound, negative iodine whole body scan, as well as combined FDG-PET/ldCT and MRI examinations. Neck compartments in FDG-PET/ldCT and MRI examinations were independently analyzed by two blinded observers for local recurrence and nodal metastases of thyroid cancer. Consecutively, the scans were read in consensus. To explore a possible synergistic effect, FDG-PET/ldCT and MRI results were combined. Histopathology or long-term follow-up served as a gold standard. For method comparison, sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy were calculated.

Results: FDG-PET/ldCT was substantially more sensitive and more specific than MRI in detection of both local recurrence and nodal metastases. Inter-observer agreement was substantial both for local recurrence (κ = 0.71) and nodal metastasis (κ = 0.63) detection in FDG-PET/ldCT. For MRI, inter-observer agreement was substantial for local recurrence (κ = 0.69) and moderate for nodal metastasis (κ = 0.55) detection. In contrast, FDG-PET/ldCT and MRI showed only slight agreement (κ = 0.21). However, both imaging modalities identified different true positive results. Thus, the combination created a synergistic effect. The multidisciplinary consensus reading further increased sensitivity, specificity, and diagnostic accuracy.

Conclusions: FDG-PET/ldCT and MRI are complementary imaging modalities and should be combined to improve detection of local recurrence and nodal metastases of thyroid cancer in high-risk patients. The multidisciplinary consensus reading is a key element in the diagnostic approach.

Citing Articles

Match Point: Nuclear Medicine Imaging for Recurrent Thyroid Cancer in TENIS Syndrome-Systematic Review and Meta-Analysis.

Gelardi F, Lazar A, Ninatti G, Pini C, Chiti A, Luster M J Clin Med. 2024; 13(18).

PMID: 39336848 PMC: 11432630. DOI: 10.3390/jcm13185362.


Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer.

Piscopo L, Nappi C, Volpe F, Romeo V, Nicolai E, Gallicchio R Cancers (Basel). 2022; 14(12).

PMID: 35740623 PMC: 9220891. DOI: 10.3390/cancers14122958.


Head-to-Head Comparison of Neck F-FDG PET/MR and PET/CT in the Diagnosis of Differentiated Thyroid Carcinoma Patients after Comprehensive Treatment.

Song Y, Liu F, Ruan W, Hu F, Younis M, Gao Z Cancers (Basel). 2021; 13(14).

PMID: 34298651 PMC: 8307331. DOI: 10.3390/cancers13143436.


Imaging and Imaging-Based Management of Pediatric Thyroid Nodules.

Iakovou I, Giannoula E, Sachpekidis C J Clin Med. 2020; 9(2).

PMID: 32024056 PMC: 7074552. DOI: 10.3390/jcm9020384.


Predictive value of LN metastasis detected by F-FDG PET/CT in patients with papillary thyroid cancer receiving iodine-131 radiotherapy.

Li C, Zhang J, Wang H Oncol Lett. 2019; 18(2):1641-1648.

PMID: 31423231 PMC: 6607093. DOI: 10.3892/ol.2019.10500.


References
1.
Dammann F, Bootz F, Cohnen M, Hassfeld S, Tatagiba M, Kosling S . Diagnostic imaging modalities in head and neck disease. Dtsch Arztebl Int. 2014; 111(23-24):417-23. PMC: 4078224. DOI: 10.3238/arztebl.2014.0417. View

2.
Daftary A . PET-MRI: Challenges and new directions. Indian J Nucl Med. 2010; 25(1):3-5. PMC: 2934593. DOI: 10.4103/0972-3919.63590. View

3.
Weber T, Ohlhauser D, Hillenbrand A, Henne-Bruns D, Reske S, Luster M . Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma. Horm Metab Res. 2012; 44(12):904-8. DOI: 10.1055/s-0032-1316351. View

4.
Freudenberg L, Antoch G, Frilling A, Jentzen W, Rosenbaum S, Kuhl H . Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging. 2008; 35(5):950-7. DOI: 10.1007/s00259-007-0634-8. View

5.
Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H . Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1998; 24(11):1342-8. DOI: 10.1007/s002590050158. View